Loading...
Pharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data
BACKGROUND: While HIV, AIDS and atypical Mycobacterium infections are closely linked, the use of Integrase-Inhibitor based cART, notably raltegravir-based regimens is more widespread. RAL should be double-dosed to 800 mg semi-daily in situation of rifampicin co-medication, because RAL is more rapidl...
Saved in:
| Published in: | AIDS Res Ther |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
BioMed Central
2015
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4297374/ https://ncbi.nlm.nih.gov/pubmed/25598834 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12981-014-0041-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|